Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Medical Genetics

Looking Ahead: Long-Term Outlook and Surveillance

At a Glance

While Congenital Disorder of Glycosylation (CDG) is a lifelong condition, many children stabilize after infancy. Long-term management shifts from acute medical care to routine health surveillance of the heart, liver, and endocrine systems, alongside physical and speech therapies to maximize independence.

Thinking about the future when your child has a rare diagnosis like CDG can feel overwhelming. However, understanding the long-term outlook can help you move from a state of emergency to a state of active management. While CDG is a lifelong journey, many children reach a period of stability where the focus shifts from survival to enhancing their quality of life and independence [1][2].

The Two Main Stages of CDG

For many children, particularly those with the most common form (PMM2-CDG), the condition is often described in two primary phases:

  1. The Infantile-Multisystem Stage: The first few years of life are often the most intense. Medical care focuses on “acute” issues like managing infections, monitoring liver function, and stabilizing blood clotting [3][4].
  2. The Stable and Developmental Stage: As children grow into their school-age years and beyond, the multisystem “flares” often settle down. The focus then shifts to rehabilitation—helping the child gain as much function, mobility, and communication as possible [1][5].

How Genetics Influence the Path

The specific genetic “spelling errors” (variants) your child has can provide clues about what to watch for most closely. Please note: there are hundreds of different variants, and you should not panic if you do not see your child’s specific variants listed here. These are just common examples.

  • The p.Val231Met Variant: This specific variant in the PMM2 gene is known to have a stronger impact on the heart. Children with this variant require more frequent cardiac surveillance (heart checks) because they have a higher risk of heart muscle issues or fluid around the heart [6].
  • The p.Arg141His Variant: This is the most common pathogenic variant in PMM2-CDG. However, it is never seen as a double copy (homozygous) in living children; it must be paired with a different variant (compound heterozygous) to cause the disease. Identifying this variant helps confirm the diagnosis and genetic pattern for the family.

Your Long-Term Surveillance Calendar

Because CDG is a “multisystem” condition, “staying ahead” of the disease requires regular check-ups, even when your child seems to be doing well.

System What is Monitored Frequency (General)
Heart EKG and Echocardiogram (ultrasound). [7] Annually for first 5 years, then every 2–3 years.
Liver Blood tests (enzymes) and ultrasounds to check for scarring (fibrosis). [8] At least annually, or more often if enzymes are high.
Endocrine Blood sugar, thyroid function, and growth hormone. [9] Annually; more frequent during puberty.
Eyes Checking for “retinitis pigmentosa” (vision changes). [10] Every 1–2 years.

The Power of Early Intervention

There is a saying in the rare disease community: “Start early, stay consistent.” While we cannot yet “fix” the genetic glitch in most types of CDG, early intervention is the most powerful tool we have to improve a child’s lifespan and quality of life [11][1].

  • Physical Therapy: Focuses on core strength and balance to help with “ataxia” (coordination issues) [1].
  • Speech Therapy: Helps with communication, whether through verbal speech or “AAC” (Assistive and Augmentative Communication) devices.
  • Occupational Therapy: Supports daily living skills, like feeding and dressing.

A Note of Hope

Recent research shows that even though the cerebellum (the part of the brain responsible for balance) may show some shrinkage on an MRI, many children with CDG actually show improvement in their coordination and motor skills over time with consistent therapy [2]. Your child’s brain is resilient, and they will continue to learn and grow in their own unique way.

Common questions in this guide

How does CDG progress as my child grows?
For many children with CDG, the condition shifts from an infantile stage with frequent acute medical issues to a more stable developmental stage. As they reach school age, the focus often moves toward rehabilitation therapies to improve coordination, mobility, and communication.
What routine medical screenings are needed for CDG?
Because CDG affects multiple systems, routine monitoring is vital to stay ahead of complications. This typically includes regular heart evaluations, liver enzyme checks, endocrine tests for growth and puberty, and eye exams to monitor for vision changes.
Do specific CDG genetic variants affect long-term health risks?
Yes, the specific genetic variant your child has can provide clues about which organs need closer monitoring. For example, children with the p.Val231Met variant in the PMM2 gene have a higher risk of heart issues and require more frequent cardiac checks.
How can early intervention therapies help a child with CDG?
Early and consistent therapies are the most effective ways to improve your child's quality of life. Physical therapy helps with core strength and ataxia, speech therapy supports communication, and occupational therapy assists with daily living skills like feeding and dressing.
What is the Nijmegen CDG severity score used for?
The Nijmegen CDG severity score is a standardized clinical tool that doctors use to track disease progression and evaluate how a child with CDG is developing over time. It helps the medical team adjust therapy goals and monitor physical milestones.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my child's specific genetic variants, and do they have a known link to higher cardiac or other systemic risks?
  2. 2.Can we review the 'long-term surveillance calendar' for my child—when are the next heart, liver, and endocrine screenings?
  3. 3.How do we know if my child has moved from the 'infantile stage' to the 'stable and developmental stage,' and how will our therapy goals change?
  4. 4.Is there a standardized tool, like the Nijmegen CDG severity score, we can use to track my child's progress over the coming years?
  5. 5.What are the specific signs of puberty or growth we should watch for, given that CDG can affect hormone levels?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Motor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.

    Bossier C, Stark C, Martakis K, et al.

    Journal of musculoskeletal & neuronal interactions 2024; (24(1)):12-21.

    PMID: 38427364
  2. 2

    A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG).

    Serrano NL, De Diego V, Cuadras D, et al.

    Orphanet journal of rare diseases 2017; (12(1)):155 doi:10.1186/s13023-017-0707-0.

    PMID: 28915903
  3. 3

    Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.

    Wicker C, Roux CJ, Goujon L, et al.

    Molecular genetics and metabolism 2023; (140(3)):107674 doi:10.1016/j.ymgme.2023.107674.

    PMID: 37542768
  4. 4

    Revisiting the immunopathology of congenital disorders of glycosylation: an updated review.

    Pascoal C, Francisco R, Mexia P, et al.

    Frontiers in immunology 2024; (15()):1350101 doi:10.3389/fimmu.2024.1350101.

    PMID: 38550576
  5. 5

    Instrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis.

    Cirnigliaro L, Pettinato F, Valle MS, et al.

    Orphanet journal of rare diseases 2024; (19(1)):39 doi:10.1186/s13023-024-03027-x.

    PMID: 38308356
  6. 6

    Clinical severity and cardiac phenotype in phosphomannomutase 2-congenital disorders of glycosylation : Insights into genetics and management recommendations.

    Holubova V, Barone R, Grunewald S, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12826 doi:10.1002/jimd.12826.

    PMID: 39633515
  7. 7

    Cardiomyopathy, an uncommon phenotype of congenital disorders of glycosylation: Recommendations for baseline screening and follow-up evaluation.

    Zemet R, Hope KD, Edmondson AC, et al.

    Molecular genetics and metabolism 2024; (142(4)):108513 doi:10.1016/j.ymgme.2024.108513.

    PMID: 38917675
  8. 8

    Liver manifestations in a cohort of 39 patients with congenital disorders of glycosylation: pin-pointing the characteristics of liver injury and proposing recommendations for follow-up.

    Starosta RT, Boyer S, Tahata S, et al.

    Orphanet journal of rare diseases 2021; (16(1)):20 doi:10.1186/s13023-020-01630-2.

    PMID: 33413482
  9. 9

    Suspected Central Adrenal Insufficiency in a Patient with Phosphomannomutase 2-Congenital Disorder of Glycosylation.

    Ødum SF, Grønborg SW, Main KM, Klose M

    JCEM case reports 2025; (3(11)):luaf237 doi:10.1210/jcemcr/luaf237.

    PMID: 41080975
  10. 10

    [Clinical and genetic analysis for two children with congenital disturbance of glycosylation with PMM2 gene mutations].

    Ren C, Fang F, Huang Y, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2015; (53(12)):938-42.

    PMID: 26887550
  11. 11

    [Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].

    Zhou SY

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2023; (25(2)):223-228 doi:10.7499/j.issn.1008-8830.2209049.

    PMID: 36854702

This page provides educational information about the long-term outlook and routine surveillance for CDG. Always consult your child's medical geneticist or pediatrician for personalized screening recommendations and care plans.

Get notified when new evidence is published on Congenital disorder of glycosylation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.